Tenax Therapeutics, Inc.
TENX•NASDAQ•Healthcare•Biotechnology

About Tenax Therapeutics

Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOChristopher Giordano
Founded1967
Employees6
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.tenaxthera.com
Phone919 855 2100
Address
101 Glen Lennox Drive, Suite 300 Chapel Hill, North Carolina 27517 United States

Corporate Identifiers

CIK0000034956
CUSIP88032L209
ISINUS88032L6056
EIN26-2593535
SIC2834

Leadership Team & Key Executives

Christopher T. Giordano
Chief Executive Officer, President and Director
Dr. Stuart Rich M.D.
Chief Medical Officer and Director
Thomas A. McGauley
Chief Financial Officer and Principal Financial Officer and Principal Accounting Officer
Doug Randall
Chief Business Officer
Dr. Douglas Hay Ph.D.
Executive Vice President of Regulatory Affairs